top of page
Tailored AI vs Generalist Models: A Federated Approach to Blood-Brain-Barrier Permeability
In drug discovery, few challenges are as persistent and as costly as predicting whether a molecule will cross the blood-brain barrier (BBB) – a crucial property for central nervous system indications, but often a liability for others. It’s a problem that sits at the intersection of chemistry, biology, and data, and one that even state-of-the-art AI models struggle with. At Qubigen, we investigated whether our AI Engine, tailored to client-specific data using our Federated AI
39 minutes ago5 min read
Qubigen Launches Collaborative Federated AI Antiviral Drug Design Project
Qubigen is pleased to announce the launch of a new collaborative Federated AI drug design project focused on the development of novel antiviral small molecules for emerging infectious diseases. This initiative reflects Qubigen’s commitment to shortening development timelines and advancing next-generation drug discovery through secure, collaborative AI technologies. Enabling Secure Multi-Party Drug Design with Qubigen’s FedAIDD This multi-party initiative consists of nonprofit
1 day ago3 min read
Qubigen Announces a Collaboration with Viva Biotech in AI-Driven Drug Discovery
Qubigen is pleased to announce a new collaboration with Viva Biotech, a global leader in AI-enabled drug discovery. Through this partnership, we will actively explore areas where traditional computational tools fall short, notably in the domain of failed (‘dark’) reaction data. The collaboration brings together Viva Biotech’s advanced Artificial Intelligence Drug Discovery (AIDD) capabilities with Qubigen’s expertise in synthetic feasibility and reaction prediction AI models.
Apr 232 min read
bottom of page